Abiopharma

🔍 Lemoine Natalie B. (Executive)

Company: HOME BANCORP, INC. (HBCP)

Report Date: 2026-06-12

Detailed Transactions and Holdings:

• Acquired 100 shares of Common Stock (Direct)
  Date: 2026-06-12 | Code: A | equity_swap_involved: 0 | shares_owned_after: 8,214.00 | transaction_form_type: 4 | Footnotes: F1, F1
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-06-12 | Code: H | nature_of_ownership: ESOP | shares_owned_after: 1,641.38
• Holds 400 shares of Employee Stock Option (Right to Buy) at $35.26 per share (Derivative)
  Date: 2026-06-12 | Code: H | Expires: 2027-05-12 | shares_owned_after: 400.00 | Footnotes: F7
• Holds 500 shares of Employee Stock Option (Right to Buy) at $45.12 per share (Derivative)
  Date: 2026-06-12 | Code: H | Expires: 2028-05-23 | shares_owned_after: 500.00 | Footnotes: F8
• Holds 500 shares of Employee Stock Option (Right to Buy) at $35.85 per share (Derivative)
  Date: 2026-06-12 | Code: H | Expires: 2029-05-23 | shares_owned_after: 500.00 | Footnotes: F9
• Holds 500 shares of Employee Stock Option (Right to Buy) at $21.99 per share (Derivative)
  Date: 2026-06-12 | Code: H | Expires: 2030-03-12 | shares_owned_after: 500.00 | Footnotes: F10
• Holds 500 shares of Employee Stock Option (Right to Buy) at $36.77 per share (Derivative)
  Date: 2026-06-12 | Code: H | Expires: 2031-05-12 | shares_owned_after: 500.00 | Footnotes: F11

Footnotes:

• F1: Includes the grant of 100 restricted stock units pursuant to the Issuer's 2021 Incentive Plan that vest in equal installments at the rate of 20% per year commencing on June 12, 2027 and that may be settled only in shares of the Issuer's common stock.
• F2: Includes the grant of 1250 restricted stock units pursuant to the Issuer's 2021 Incentive Plan that vest in equal installments at the rate of 20% per year commencing on May 12, 2025, and that may be settled only in shares of the Issuer's common stock.
• F3: Includes the grant of 1300 restricted stock units pursuant to the Issuer's 2021 Incentive Plan that vest in equal installments at the rate of 20% per year commencing on May 12, 2027 and that may be settled only in shares of the Issuer's common stock.
• F4: Includes the grant of 1391 restricted stock units pursuant to the Issuer's 2021 Incentive Plan that vest in equal installments at the rate of 20% per year commencing on May 12, 2026, and that may be settled only in shares of the Issuer's common stock.
• F5: Includes the grant of 750 restricted stock units pursuant to the Issuer's 2021 Incentive Plan that vest in equal installments at the rate of 20% per year commencing on May 12, 2023, and that may be settled only in shares of the Issuer's common stock. As of July 15, 2024, 450 restricted stock units remain unvested.
• F6: Includes the grant of 800 restricted stock units pursuant to the Issuer's 2021 Incentive Plan that vest in equal installments at the rate of 20% per year commencing on May 12, 2024, and that may be settled only in shares of the Issuer's common stock. As of July 15, 2024, 640 restricted stock units remain unvested.
• F7: The options vest and become exercisable in five equal installments beginning May 12, 2018.
• F8: The options vest and become exercisable in five equal installments beginning May 23, 2019.
• F9: The options vest and become exercisable in five equal installments beginning May 23, 2020
• F10: The options vest and become exercisable in five equal installments beginning March 12, 2021.
• F11: The options vest and become exercisable in five equal installments beginning May 12, 2022.